- Tension: The brain already produces a protein that appears to reverse cognitive aging, yet its levels drop steadily as we get older, precisely when we need it most.
- Noise: Billions are spent annually on brain supplements with thin evidence, while a naturally occurring protein with robust research behind it has only just reached clinical trials.
- Direct Message: Klotho research suggests the body may already contain its own cognitive repair mechanism. The Phase 1 trial now underway will determine whether science can harness it before the supplement industry tries to sell you a knockoff.
To learn more about our editorial approach, explore The Direct Message methodology.
Researchers at the University of California, San Francisco have identified a protein called klotho, already circulating in every human body, that appears to reverse age-related cognitive decline in animal models. Now a Phase 1 clinical trial, led by UCSF neurologist Dr. Dena Dubal and her team, is moving forward to test whether a single low-dose injection of klotho can improve cognitive function in healthy older adults. The trial, announced in early 2025, represents one of the first attempts to translate decades of klotho research into a human therapeutic.
Klotho was first discovered in 1997 by Japanese researcher Dr. Makoto Kuro-o, who named it after the Greek goddess of fate who spins the thread of life. The protein is produced primarily in the kidneys and brain, and its levels decline steadily with age. Studies published in journals including Cell Reports and The Journal of Neuroscience have shown that mice injected with klotho demonstrated improved synaptic plasticity, better spatial memory, and enhanced resilience to neurodegenerative stress, even when they were old. The remarkable part: a single injection appeared to produce cognitive benefits lasting weeks, suggesting the protein triggers a cascade of downstream effects rather than simply patching a deficit.
Dr. Dubal’s lab published findings showing that people who naturally carry a genetic variant producing higher klotho levels tend to perform better on cognitive tests as they age. The correlation held across demographics and persisted even in carriers of the APOE4 gene, the strongest known genetic risk factor for Alzheimer’s disease. That finding caught the attention of the broader neuroscience community because it suggested klotho might offer protection precisely where existing interventions fall short. As DM News previously reported in a piece on how klotho could change how we treat cognitive decline, the protein’s mechanism appears to enhance the brain’s ability to form and strengthen connections between neurons rather than targeting amyloid plaques or tau tangles directly.
The timing matters for a particular reason. Americans over 50 are already spending billions annually on cognitive health products, many of which have thin evidence behind them. In my recent reporting on a popular brain supplement linked to shorter lifespan in men, I found that the gap between what people will pay for and what science actually supports is enormous. Klotho research stands apart because the biological mechanism is well-documented across multiple independent labs, and the protein already exists in the human body, reducing concerns about foreign-substance toxicity that plague many pharmaceutical candidates.
The Phase 1 trial will focus on safety and dosing in a small cohort of adults over 65. Researchers will measure not just adverse effects but cognitive performance on standardized tests over a 90-day period following a single subcutaneous injection. If results are promising, a larger Phase 2 trial could begin as early as 2027. Dr. Dubal has noted in interviews that the goal is to determine whether exogenous klotho can replicate the cognitive advantages seen in people who naturally produce more of it. The research has attracted funding from the National Institutes of Health, the Simons Foundation, and several private donors.
There are real caveats. Animal models frequently fail to translate to humans, and cognitive improvement is notoriously difficult to measure in short-term trials. Klotho’s effects on organs beyond the brain, particularly the kidneys and cardiovascular system, will need careful monitoring. As We explored in an article on Americans between 50 and 65 rationing medication while waiting for Medicare, the population most likely to benefit from a cognitive aging treatment is also the population least likely to have access to it early. Pricing, insurance coverage, and distribution will shape whether klotho, if it works, becomes a breakthrough for everyone or a luxury for the few. For now, the science is moving from understanding what accelerates aging toward something more ambitious: the possibility that the body already contains what it needs to push back.
Feature image by Engin Akyurt on Pexels
